NCT02693535 2026-03-19
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
Clinical Trials
35 trialsNCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT05325632 2026-03-02
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07053085 2026-02-27
A Study of Surgery and Radiotherapy in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06348134 2026-02-17
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
University of Chicago
Phase 2 Recruiting
NCT04588545 2026-02-09
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Recruiting
NCT07393425 2026-02-06
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT06876714 2026-02-04
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT07340398 2026-01-21
TAYLOR
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT05256745 2025-12-24
RAGE
Georgetown University
Phase 1/2 Recruiting
NCT03803553 2025-12-23
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
Massachusetts General Hospital
Phase 3 Recruiting
NCT05786716 2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05722886 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT04329065 2025-11-06
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
University of Washington
Phase 2 Recruiting
NCT05760612 2025-09-25
Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting
NCT06145308 2025-09-15
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Phase 2 Recruiting
NCT05900206 2025-09-02
ARIADNE
Karolinska University Hospital
Phase 2 Recruiting
NCT06490536 2025-08-29
The Sagittarius Trial
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 3 Recruiting
NCT04341181 2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT06441890 2025-07-14
BRE-10
University of Illinois at Chicago
Phase 2 Recruiting
NCT06439693 2025-06-26
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05319873 2025-05-13
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT04680442 2025-04-06
SCHOLAR-2
Population Health Research Institute
Phase 2 Recruiting
NCT05332561 2025-03-20
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
German Cancer Research Center
Phase 2 Recruiting
NCT05020860 2025-02-27
RESPONSE
Baylor Breast Care Center
Phase 2 Recruiting
NCT05891561 2024-11-27
Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer
Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT06278870 2024-02-26
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting
NCT05159193 2024-02-02
Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting
NCT06162559 2024-01-11
TRAIN-4
The Netherlands Cancer Institute
Phase 1 Recruiting
NCT05978648 2023-11-30
SMA-BC-002
Sun Yat-sen University
Phase 2 Recruiting
NCT05883852 2023-06-27
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
Fudan University
Phase 3 Recruiting
NCT05638594 2023-03-20
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
Shengjing Hospital
Phase 2 Recruiting
NCT05188313 2022-06-24
TRAP-2
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 3 Recruiting
NCT04993014 2021-08-06
HER2Cell
AC Camargo Cancer Center
Phase 2 Recruiting
NCT04750122 2021-04-01
Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients
Peking University People's Hospital
Phase 1/2 Recruiting